SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-010354
Filing Date
2024-03-18
Accepted
2024-03-18 17:15:30
Documents
59
Period of Report
2024-01-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 854700
2 ex31-1.htm EX-31.1 17861
3 ex31-2.htm EX-31.2 18163
4 ex32-1.htm EX-32.1 6891
5 ex32-2.htm EX-32.2 6797
  Complete submission text file 0001493152-24-010354.txt   4584522

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE bctx-20240131.xsd EX-101.SCH 31053
7 XBRL CALCULATION FILE bctx-20240131_cal.xml EX-101.CAL 38429
8 XBRL DEFINITION FILE bctx-20240131_def.xml EX-101.DEF 184736
9 XBRL LABEL FILE bctx-20240131_lab.xml EX-101.LAB 265849
10 XBRL PRESENTATION FILE bctx-20240131_pre.xml EX-101.PRE 231708
62 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 791151
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 10-Q | Act: 34 | File No.: 001-40101 | Film No.: 24760052
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)